PET Imaging of Cyclooxygenases in Neuroinflammation

Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2

“…There has also been significant progress in the development of COX-2-targeting radioligands for imaging inflammation, cancer, and neurological disorders [54][55][56][57]. Over the last decades, a variety of radionuclide-based imaging agents have been developed by the incorporation of radioisotopes such as 11 C, 18 F, 99m Tc, 123 I, and 125 I into NSAIDs and related compounds [55,56,[58][59][60][61][62][63][64][65][66][67][68][69][70][71]. Selected examples of PET radioligands for COX-2 imaging are presented in Figure 3 Molecules 2022, 27, x FOR PEER REVIEW 3 of 20…”

“…There has also been significant progress in the development of COX-2-targeting radioligands for imaging inflammation, cancer, and neurological disorders [54][55][56][57]. Over the last decades, a variety of radionuclide-based imaging agents have been developed by the incorporation of radioisotopes such as 11 C, 18 F, 99m Tc, 123 I, and 125 I into NSAIDs and related compounds [55,56,[58][59][60][61][62][63][64][65][66][67][68][69][70][71]. Selected examples of PET radioligands for COX-2 imaging are presented in Figure 3 A major focus involves 18 F-labeled radioligands, due to their favourable half-life (t1/2 = 109.8 min), ease of production, the availability of a variety of radiofluorination methods, and better imaging characteristics of the short-lived positron emitter 18 F. This review article primarily covers 18 F-labeled radioligands reported in the last decade for targeting COX-2.…”